UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

RTTNews | 457 days ago
Stocktwits
UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

(RTTNews) - Biotech company UroGen Pharma Ltd. (URGN) announced Wednesday that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd. (TEVA), alleging infringement of U.S. Patent Numbers 9,040,074 and 9,950,069.

Both patents are listed in the U.S. Food and Drug Administration's (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations for JELMYTO (mitomycin) for pyelocalyceal solution.

JELMYTO is indicated for the treatment of adults with low-grade, upper tract urothelial cancer and utilizes UroGen's RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology.

The lawsuit follows an Abbreviated New Drug Application filed by Teva Pharmaceuticals, Inc., which seeks authorization from the FDA to manufacture, use or sell a generic version of mitomycin for pyelocalyceal solution, 40 mg/vial in the United States before the expiry of the '074 and '069 patents.

Tags: TEVA URGN
Stocktwits
read more
Teva Pharmaceuticals Says Generic Version Of Forteo Approved In U.S

Teva Pharmaceuticals Says Generic Version Of Forteo Approved In U.S

Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced Friday the approval of a generic version of Forteo in the United States. Forteo had annual sales of $609 million as of July 2023, according to IQVIA data.
RTTNews | 595 days ago
Teva Pharma Boosts FY23 Revenue Outlook - Update

Teva Pharma Boosts FY23 Revenue Outlook - Update

While reporting financial results for the third quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings guidance for the full-year 2023, while raising annual revenue outlook.
RTTNews | 604 days ago
Teva Pharma Boosts FY23 Revenue Outlook - Update

Teva Pharma Boosts FY23 Revenue Outlook - Update

While reporting financial results for the second quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings guidance for the full-year 2023, while raising annual revenue outlook.
RTTNews | 702 days ago
Teva Pharma Reaffirms FY23 Outlook - Update

Teva Pharma Reaffirms FY23 Outlook - Update

While reporting financial results for the first quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings and revenue guidance for the full-year 2023.
RTTNews | 786 days ago
Teva Recalls FENTANYL Buccal Tablets CII

Teva Recalls FENTANYL Buccal Tablets CII

Teva Pharmaceuticals USA is recalling specific lots of various strengths of FENTANYL Buccal Tablets CII to the consumer level citing a labeling error, the U.S. Food and Drug Administration said. The recall has been initiated because safety updates were omitted in the product insert/medication guide that are provided with these recalled lots.
RTTNews | 795 days ago
Teva Pharmaceutical Appoints Eric Hughes As Chief Medical Officer

Teva Pharmaceutical Appoints Eric Hughes As Chief Medical Officer

Teva Pharmaceutical Industries Ltd. (TEVA) announced Friday the appointment of Dr. Eric Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer. Hughes will begin his employment on August 1, 2022, and will be based out of Teva's U.S. headquarters in Parsippany, New Jersey.
RTTNews | 1099 days ago
Tools
Economic Calendar
Market Hours
Interest Rates
Holidays Calendar
Forex Market
Forex Volatility
Forex Correlation
Forex News
forex analysis
COT Data
Liquidity
Forex Calculators
Forex Heat Map
Indicators Heatmap
Community
Community
Systems
Most Popular Systems
Strategies
Contests
Forex Charts
Forex Sentiment
Sentiment Indicator
Reviews
Brokers
Prop Trading Firms
VPS Services
Signal Providers
EA Programming Services
Affiliate Programs
PAMM Broker Services
Rebate Program Services
Trading Platforms
Expert Advisors
Crypto Exchanges
Trading Courses
Brokers
Forex Spreads
Forex Broker Quotes
Forex Broker Swaps
Forex Broker Volume
Forex Broker Promotions Press Release
Platform
Widgets
Features
API
RSS
Stock Portfolio
Affiliate Software
Advanced Charts
Support
FAQ
Help
Contact Us
Report a Bug!
About
Blog
© 2025 Myfxbook Ltd. All Rights Reserved.
HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.